Introduction {#section5-2040620719839025}
============

Multiple myeloma (MM) is a systemic malignancy of plasma cells in bone marrow, with approximately 30,280 incident cases estimated to be diagnosed in the United States in 2017 (17,940 men and 12,790 women). MM primarily affects the elderly population since the median age at incidence is 69 years.^[@bibr1-2040620719839025],[@bibr2-2040620719839025]^ For several decades, the standard treatment approach has been induction therapy followed by autologous stem-cell transplantation for transplant-eligible patients and high-dose chemotherapy for other patients. While the recent introduction of many novel therapies such as immunomodulating agents, proteasome inhibitors (PIs), monoclonal antibodies, and histone deacetylase inhibitor have shown improved response, progression-free survival^[@bibr3-2040620719839025][@bibr4-2040620719839025][@bibr5-2040620719839025][@bibr6-2040620719839025][@bibr7-2040620719839025][@bibr8-2040620719839025]--[@bibr9-2040620719839025]^ and survival rates^[@bibr10-2040620719839025]^ in clinical trials, MM remains an incurable malignancy for the majority of patients.^[@bibr11-2040620719839025]^

Peripheral neuropathy (PN) is a common complication of MM and one of the main dose-limiting iatrogenic toxicities associated with some antimyeloma treatments, including older-generation PIs such as bortezomib.^[@bibr12-2040620719839025][@bibr13-2040620719839025][@bibr14-2040620719839025][@bibr15-2040620719839025]--[@bibr16-2040620719839025]^ The incidence of PN associated with MM treatments during the course of the disease and treatment has been estimated to range between 21% and 70% depending on the treatment and PN severity.^[@bibr15-2040620719839025]^ MM treatment options are often limited by the likelihood of therapies causing or exacerbating neuropathies with significant negative impacts on patient quality of life.^[@bibr14-2040620719839025],[@bibr16-2040620719839025]^ Treatment-induced PN, although usually reversible, can cause severe pain and affect the patient's activities of daily living, as well as causing serious problems, such as loss of sensation, balance issues, muscle weakness, and organ failure.^[@bibr15-2040620719839025][@bibr16-2040620719839025][@bibr17-2040620719839025]--[@bibr18-2040620719839025]^

Management of PN is an ongoing challenge for healthcare providers. Actions to mitigate the incidence and effects of PN may include dosage and dosing-schedule adjustments of PIs, PI treatment discontinuation, other modalities (e.g. electrical nerve stimulation, physical therapy, acupuncture, other), and medications to address the pain (e.g. topical analgesics, antidepressants, antiepileptics, opioids).^[@bibr16-2040620719839025],[@bibr19-2040620719839025]^ These treatment measures for managing the effects of PN also carry an economic burden for the healthcare system (e.g. increased visits to monitor or treat the PN, costs of PN treatment), as well as significant financial and lifestyle repercussions for the MM patient.

The impact of PN on healthcare utilization and costs for MM patients treated in real-world practice settings is not well understood. The purpose of this study was to use real-world data to examine the healthcare resource utilization and costs associated with PN in patients being treated for MM, comparing those diagnosed with PN to a matched control cohort without PN.

Methods {#section6-2040620719839025}
=======

Study design and data source {#section7-2040620719839025}
----------------------------

This retrospective, observational cohort study was based on administrative healthcare claims data from 1 January 2006 to 28 February 2017 from the IBM® MarketScan Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare) databases. These databases include inpatient medical, outpatient medical, and outpatient pharmacy claims data, as well as insurance enrollment and demographic information collected from a wide variety of health plans across the US. The Commercial database includes information for over 20 million individuals annually who are under the age of 65 years with employer-sponsored health insurance, including the primary insured, spouses and dependents. The Medicare Supplemental database includes both the Medicare-paid and supplemental-paid components of reimbursed insurance claims information for over 2 million individuals annually with both traditional and supplemental Medicare coverage. The study databases satisfy Sections 164.514 (a)--(b)(1)(ii) of the Health Insurance Portability and Accountability Act of 1996 privacy rule (HIPAA) regarding the determination and documentation of statistically de-identified data. This study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, and therefore institutional review board approval was not required.

Patient identification {#section8-2040620719839025}
----------------------

Selected adult patients, 18 years of age and older, had at least one inpatient or two outpatient claims (from 30 to 365 days of the first found outpatient claim) with a diagnosis of MM based on International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) diagnosis codes 203.0x or ICD-10-CM (tenth revision) diagnosis codes C9000, C9001 and C9002 between 1 July 2006 and 28 February 2017, and at least one claim indicating the administration or prescription of an MM therapy (bendamustine, bortezomib, carfilzomib, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposomal, lenalidomide, melphalan, panobinostat, pomalidomide, thalidomide) on or after the date of the first MM diagnosis. Claims associated with a diagnostic workup such as laboratory tests or diagnostic X-rays were not used for patient selection. To ensure that patients were newly diagnosed and newly treated, a 12-month period with no diagnosis of MM prior to the first found (initial) MM diagnosis and a 12-month period with no MM therapy prior to the initial MM therapy was required. The index date was the date of the first claim for one of the MM therapies on or after the initial MM diagnosis. Continuous medical and prescription coverage was required for at least 12 months prior to the index date (preperiod), and for at least 3 months after the index date (postperiod). Patients were followed from the index date until the earliest evidence of inpatient death (*via* discharge status), end of continuous enrollment, or end of study period (28 February 2017). This process is described in [Figure 1](#fig1-2040620719839025){ref-type="fig"}.

![Patient selection flowchart.\
ICD-9-CM, International Classification of Diseases, ninth revision, Clinical Modification; ICD-10-CM, tenth revision; MM, multiple myeloma; PN, peripheral neuropathy.](10.1177_2040620719839025-fig1){#fig1-2040620719839025}

Identification of peripheral neuropathy cases and matched controls {#section9-2040620719839025}
------------------------------------------------------------------

Due to the lack of diagnosis code specificity for disease-related or treatment-induced PN, PN was identified using an algorithm from previously published studies.^[@bibr20-2040620719839025],[@bibr21-2040620719839025]^ PN cases were identified by a medical claim with a diagnosis for PN (codes in [Table A.1](#table5-2040620719839025){ref-type="table"}) during the 9 months following their initial MM therapy and without evidence of PN during the 12-month preperiod through the 7 days following the initial MM treatment ([Figure 2](#fig2-2040620719839025){ref-type="fig"}). Controls had no medical claims with a diagnosis of PN anytime during the 12-month preperiod and throughout the follow-up period.

![PN definition at the patient level.\
MM, multiple myeloma; PN, peripheral neuropathy.](10.1177_2040620719839025-fig2){#fig2-2040620719839025}

To adjust for imbalances in demographics and clinical characteristics, patients with PN were matched to a pool of patients without PN in a ratio of 1:2 (PN:without PN) using propensity-score modeling with nearest-neighbor matching. Matching factors included patients' demographic characteristics \[age, sex, geographic region of residence, payer (Commercial or Medicare), healthplan type\] and baseline clinical characteristics (Deyo--Charlson Comorbidity Index, DCI)^[@bibr22-2040620719839025]^ and specific preindex comorbidities including cardiovascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, chronic kidney disease, skeletal-related events, coagulopathies, hematologic disease, hypertension, and the index MM medication). Standardized differences in matching factors between patients with PN and patients without PN were calculated before and after the matching to examine the quality of the match.

Lines of therapy {#section10-2040620719839025}
----------------

This study used a previously published MM treatment algorithm to identify the number of lines of therapy.^[@bibr21-2040620719839025]^ The first line started on the date of the first MM chemotherapy or immunotherapy treatment with bendamustine, bortezomib, carfilzomib, cisplatin, cyclophosphamide, doxorubicin, doxorubicin liposomal, lenalidomide, melphalan, panobinostat, pomalidomide, or thalidomide. A treatment regimen was defined as consisting of one or more chemotherapy with or without immunotherapy agents administered within 90 days of the start of the line of therapy. A line of therapy ended at the earliest occurrence of a 90-day gap in all MM treatments in a regimen comprising the line of therapy, initiation of a different MM treatment \> 90 days after the start of current line of therapy, inpatient discharge status of death, end of enrollment, or end of data. Note that lenalidomide monotherapy initiated within 60 days of the last drug administration in the line of therapy was classified as 'maintenance therapy'. Maintenance therapy was considered to be a continuation of the line of therapy and not a new line of therapy. Moreover, any MM therapy received within 90 days following a stem-cell transplant date was considered to be 'consolidation therapy' within the current line and not the start of a new line of therapy. All subsequent lines of therapy were identified using the same approach as for the first line (with the noted exception above regarding first-line maintenance). [Figure 3](#fig3-2040620719839025){ref-type="fig"} describes two examples of changes in treatment regimen and how lines of therapy were defined.

![Examples of switching in regimens.\
(a) Switch in treatment regimen; (b) addition to treatment regimen.](10.1177_2040620719839025-fig3){#fig3-2040620719839025}

Patients with and without PN were identified during each line of therapy. Because of the small number of patients with more than three lines of therapy with PN, the third line and subsequent lines were combined in reporting.

Covariates and study outcomes {#section11-2040620719839025}
-----------------------------

Demographics data extracted on the index date, included age, sex, US Census Bureau geographic region, payer (Commercial insurance or Medicare), healthplan type, and index year. Baseline clinical characteristics, measured throughout the 12-month pre-index period, included the DCI (an aggregate measure of comorbidity expressed as a numeric score based on the presence of various diagnoses), specific conditions contained in the DCI, other primary cancers, and other disease-related complications.^[@bibr22-2040620719839025]^

Study outcomes included all-cause healthcare utilization and costs measured during the at-least-3-month follow-up period and stratified for occurrence during the first, second, or third (or higher) lines of therapy. Healthcare utilization and costs were categorized as inpatient medical, emergency department/room (ER), office visits, outpatient hospital-based visits, other outpatient services, and outpatient pharmacy. Due to the variable length of follow up for patients overall and during lines of therapy, healthcare utilization and costs were reported in per-patient-per-month units (PPPM). Costs used the total paid amounts from all payers to all providers, including plan-paid, patient-paid, and coordinated benefit payments. All dollar amounts were inflation adjusted to 2017 US dollars using the Medical Care component of the Consumer Price Index.^[@bibr23-2040620719839025]^

The incidence rate of PN was calculated using the unmatched sample of all treated MM patients as the number of patients with PN divided by the person-time from the index date to the first PN diagnosis for PN patients, plus the person-time from the index date to the end of follow up for patients without PN.

Statistical considerations {#section12-2040620719839025}
--------------------------

Pairwise descriptive statistics were used to compare demographics, comorbid conditions, healthcare utilization and costs between patient cohorts with and without PN after propensity-score matching. Descriptive statistics also evaluated these differences between the comparator cohorts during first line, second line, and third-plus-subsequent lines of therapy. Chi-squared tests were conducted for differences in dichotomous or categorical variables and *t* tests were conducted for comparisons of continuous variables. A *p* value \< 0.05 was set as the threshold for statistically significant differences. Following propensity-score matching of PN patients and patients without PN, statistically significant postindex differences in results between cohorts were presumed to be associated with the effects of the key independent variable, the incidence of PN. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, US).

Results {#section13-2040620719839025}
=======

A total of 9207 patients comprising the case and control pool; 15.5% (1431 patients) were identified as having PN; 7776 had no PN diagnosis anytime during the study period ([Figure 1](#fig1-2040620719839025){ref-type="fig"}). The incidence rate for a mean (standard deviation) duration of 624 (594) days after an initial MM diagnosis until PN was identified or end of follow up was estimated as 9.1 PN cases per 100 person-years.

Following matching, the study cohorts consisted of 1387 MM patients with PN and 2594 patients without any PN diagnosis during the study period. These matched study cohorts were well balanced with no statistically significant differences in demographics or baseline clinical characteristics ([Tables 1](#table1-2040620719839025){ref-type="table"}). Mean patient age was 64 years, with 60--61% males, and 43--44% covered by Medicare. The length of follow up was longer for PN patients at a mean (SD) of 788 (580) days and 693 (571) days for non-PN patients ([Table 1](#table1-2040620719839025){ref-type="table"}). Among the 1387 MM patients with PN, the mean (SD) and median duration from index date to PN diagnosis was 129 (68) days and 125 days, respectively.

###### 

Demographic and baseline clinical characteristics.

![](10.1177_2040620719839025-table1)

                                                                                        PN cases      Non-PN controls   *p* value   Standard difference
  ------------------------------------------------------------------------------------- ------------- ----------------- ----------- ---------------------
  **Age, mean (SD) years**                                                              63.9 (10.8)   64.2 (11.6)       0.314       3.39
   18--44                                                                               0.4%          0.3%              0.395       2.75
   45--54                                                                               2.7%          3.7%              0.084       5.89
   55--64                                                                               16.4%         15.9%             0.692       1.31
   65--74                                                                               37.1%         37.8%             0.670       1.42
   75+                                                                                  25.5%         20.7%             0.001       11.38
  **Sex, %**                                                                                                                        
   Male                                                                                 60.6%         60.1%             0.725       1.17
   Female                                                                               39.4%         39.9%             0.725       1.17
  **Payer, %**                                                                                                                      
   Commercial                                                                           55.6%         57.0%             0.399       2.80
   Medicare                                                                             44.4%         43.0%             0.399       2.80
  **Insurance plan type, %**                                                                                                        
   Preferred-provider organization                                                      55.7%         56.2%             0.740       1.10
   Comprehensive                                                                        19.6%         19.0%             0.623       1.63
   Health-maintenance organization                                                      11.6%         11.7%             0.945       0.23
   Point of service                                                                     5.3%          5.4%              0.818       0.77
   Other                                                                                7.9%          7.7%              0.867       0.55
  **Geographic region, %**                                                                                                          
   Northeast                                                                            17.8%         17.8%             0.975       0.11
   North central                                                                        28.8%         27.9%             0.552       1.97
   South                                                                                35.4%         37.6%             0.166       4.62
   West                                                                                 17.2%         15.3%             0.114       5.22
   Unknown                                                                              0.7%          1.3%              0.109       5.55
  **Length of follow up, mean (SD) days**                                               788 (580)     693 (571)         \<0.001     16.52
   Median follow up (days)                                                              642           522                           
  **Deyo--Charlson Comorbidity Index, mean (SD)**                                       4.5 (2.9)     4.4 (2.8)         0.999       3.69
  **Comorbid conditions** ^[\$](#table-fn3-2040620719839025){ref-type="table-fn"}^                                                  
   Hypertension                                                                         62.5%         59.9%             0.109       5.34
   Skeletal-related events                                                              48.4%         48.4%             0.980       0.08
   Diabetes                                                                             30.1%         25.9%             0.004       9.43
   Renal disease                                                                        23.0%         21.0%             0.155       4.71
   Ischemic vascular condition^[‡](#table-fn4-2040620719839025){ref-type="table-fn"}^   22.5%         22.4%             0.922       0.32
   Chronic kidney disease                                                               19.4%         18.6%             0.532       2.07
   Anemia or anemia treatment                                                           57.0%         56.1%             0.569       1.89
   Chronic pulmonary disease                                                            16.4%         15.4%             0.435       2.59
   Hypercalcemia                                                                        14.0%         13.3%             0.523       2.12
   GI bleeding                                                                          5.0%          5.2%              0.871       0.54
   Pneumonia                                                                            9.4%          9.6%              0.847       0.64
   Congestive heart failure                                                             7.8%          8.1%              0.732       1.14
   Cerebrovascular disease                                                              6.8%          6.6%              0.860       0.59
   Thrombocytopenia                                                                     7.8%          6.9%              0.282       3.55
   End-stage renal disease/renal failure                                                6.3%          6.5%              0.802       0.84
   Venous thromboembolism                                                               5.3%          5.7%              0.593       1.79
  **Prior primary cancer**                                                                                                          
   Solid tumor                                                                          24.4%         24.0%             0.805       0.82
   Hematologic cancer                                                                   12.4%         13.5%             0.331       3.25
  **Days from diagnosis to treatment, mean (SD)**                                       158 (355)     163 (360)         0.623       1.64
   Median (days)                                                                        26            27                            
  **Stem-cell transplant prior to index treatment, %**                                  0.8%          1.0%              0.588       1.83
  **Index MM therapy, %**                                                                                                           
   Bendamustine                                                                         0.2%          0.6%              0.081       6.22
   Bortezomib                                                                           52.5%         50.0%             0.135       4.98
   Carfilzomib                                                                          0.1%          0.2%              0.722       2.01
   Cisplatin                                                                            0.4%          0.4%              0.902       0.41
   Cyclophosphamide                                                                     9.9%          10.3%             0.733       1.14
   Doxorubicin                                                                          1.7%          1.7%              0.937       0.26
   Doxorubicin liposomal                                                                0.2%          0.2%              1.000       0.32
   Lenalidomide                                                                         37.1%         37.9%             0.620       1.65
   Melphalan                                                                            2.1%          2.8%              0.190       4.45
   Panobinostat                                                                         0.0%          0.0%              --          --
   Pomalidomide                                                                         0.1%          0.1%              1.000       0.18
   Thalidomide                                                                          4.7%          5.6%              0.244       3.93

GI, gastrointestinal; MM, multiple myeloma; PN, peripheral neuropathy; SD, standard deviation.

The standardized differences were multiplied by 100 to facilitate readers' viewing results.

Comorbid condition occurring during the preperiod in \<5% patients are not shown.

Ischemic vascular conditions include unstable angina, stable angina, ischemic stroke, transient ischemic event, and other chronic ischemic heart disease, including coronary revascularization.

The most common baseline comorbid conditions included hypertension (60--63%), skeletal-related events (48%), diabetes (26--30%), renal disease (21--23%), and ischemic vascular conditions (22%). At index, approximately 50--53% received bortezomib; 37--38% received lenalidomide; 10% received cyclophosphamide, and 5--6% received thalidomide as their initial MM therapy, with the remaining MM therapies received as index medications in less than 3% of patients ([Table 1](#table1-2040620719839025){ref-type="table"}). Of the 3981 matched patients, 1267 (32%) had a PN diagnosis and 2687 (68%) had no PN diagnosis during their first-line therapy. There were 27 patients whose PN diagnosis occurred after the end of the first line but before the start of second-line therapy. A total of 1974 patients had a second-line therapy, of which 280 patients (15%) had PN during their second line, while 1532 patients (85%) had no PN during their second line, with the remaining patients having PN during the first line, thus not eligible for the PN analysis during the second line. Of the 1103 patients with a third or subsequent line of therapy, 75 patients (7%) had a PN diagnosis and 1028 patients (93%) had no PN during their third or subsequent line. Demographic and baseline clinical characteristics measured during first-line, second-line, and third/subsequent-line therapy were similar between PN patients and patients without PN ([Tables A.2](#table6-2040620719839025){ref-type="table"}[](#table7-2040620719839025){ref-type="table"}--[A.4](#table8-2040620719839025){ref-type="table"}).

All-cause healthcare utilization {#section14-2040620719839025}
================================

Healthcare utilization was significantly higher in most healthcare use categories among patients with PN compared with patients with no PN. Significantly more PN patients had a hospitalization during follow up (77.4%) compared with patients without PN (67.2%; *p* \< 0.001), however, their length of stay was similar \[PN 0.60 (0.87) days PPPM *versus* non-PN 0.66 (0.96) days PPPM; *p* = 0.052\]. More patients with PN had an ER visit (67.8% *versus* 58.4%; *p* \< 0.001), had significantly more outpatient hospital-based visits \[mean 13.5 (14.7) visits PPPM *versus* 11.5 (18.0) visits PPPM; *p* \< 0.001\], fewer laboratory tests \[mean 4.1 (5.1) tests PPPM *versus* 4.7 (5.6) tests PPPM; *p* \< 0.001\], and outpatient prescriptions \[4.7 (2.5) prescription claims PPPM *versus* 4.2 (2.4) prescription claims PPPM; *p* \< 0.001\] compared with patients without PN ([Table 2](#table2-2040620719839025){ref-type="table"}).

###### 

Per-patient-per-month all-cause healthcare utilization over the entire follow-up period.

![](10.1177_2040620719839025-table2)

                                                      Entire follow-up period                 
  --------------------------------------------------- ------------------------- ------------- ---------
  **All-cause healthcare utilization (PPPM)**                                                 
  Patients with an inpatient admission, %             77.4%                     67.2%         \<0.001
  Admissions PPPM, mean (SD)                          0.11 (0.14)               0.10 (0.15)   0.019
   Patients with an admission, mean (SD)              0.14 (0.14)               0.15 (0.16)   0.373
  Patients with an ER visit, %                        67.8%                     58.4%         \<0.001
  ER visits PPPM, mean (SD)                           0.13 (0.33)               0.11 (0.22)   0.015
   Patients with a visit, mean (SD)                   0.19 (0.39)               0.19 (0.26)   0.629
  Patients with an outpatient office visit, N%        97.9%                     96.6%         0.024
  Outpatient office visits PPPM, mean (SD)            1.7 (1.2)                 1.6 (1.2)     0.142
   Patients with a visit, mean (SD)                   1.7 (1.2)                 1.7 (1.1)     0.342
  Patients with outpatient hospital-based visits, %   98.7%                     96.3%         \<0.001
  Outpatient hospital-based visits PPPM, mean (SD)    13.3 (14.7)               11.1 (17.8)   \<0.001
   Patients with a visit, mean (SD)                   13.5 (14.7)               11.5 (18.0)   \<0.001
  Patients with a laboratory test, %                  90.9%                     87.9%         0.003
  Laboratory tests PPPM, mean (SD)                    3.7 (5.0)                 4.1 (5.5)     0.018
   Patients with a test, mean (SD)                    4.1 (5.0)                 4.7 (5.6)     0.001
  Patients filling an outpatient prescription, %      97.2%                     97.1%         0.941
  Outpatient prescriptions PPPM, mean (SD)            4.6 (2.6)                 4.0 (2.5)     \<0.001
   Patients with a prescription, mean (SD)            4.7 (2.5)                 4.2 (2.4)     \<0.001

ER, emergency department (room); PN, peripheral neuropathy; PPPM, per patient per month; SD, standard deviation.

Use of narcotic pain medication was common and also higher among patients with PN compared with patients with no PN (during first-line therapy: 82% *versus* 72%; *p* \< 0.001).

All-cause healthcare costs {#section15-2040620719839025}
==========================

Healthcare costs were also higher among patients with PN compared with control patients with no PN and increased as patients proceeded to higher lines of therapy ([Table 3](#table3-2040620719839025){ref-type="table"}). Mean total costs for PN patients exceeded those of patients without PN by \$1509 PPPM \[PN \$16,600 (SD \$14,450) *versus* non-PN \$15,090 (SD \$13,399); *p* = 0.001\] over the entire follow-up period. This difference was primarily attributable to the first 180 days postindex, where PN patients' mean PPPM costs exceeded those of the non-PN cohort by \$3317 during the first 90 days (*p* \< 0.001), and by \$5167 during the period 91--180 days postindex (*p* \< 0.001).

###### 

Per-patient-per-month all-cause healthcare costs over the entire follow-up period.

![](10.1177_2040620719839025-table3)

                                                      Entire follow-up period                         
  --------------------------------------------------- ------------------------- --------------------- ---------
  **All-cause healthcare costs (PPPM)**                                                               
  Inpatient-admission costs, mean (SD)                \$4750 (\$9944)           \$4002 (\$8993)       0.016
  Outpatient medical costs, mean (SD)                 \$8100 (\$8,341)          \$7408 (\$8,007)      0.010
   ER costs, mean (SD)                                \$126 (\$620)             \$92 (\$374)          0.029
   Outpatient office-visit costs, mean (SD)           \$216 (\$302)             \$203 (\$329)         0.214
   Outpatient hospital-based visit costs, mean (SD)   \$4906 (\$6410)           \$4076 (\$6280)       \<0.001
   Laboratory-testing costs, mean (SD)                \$144 (\$309)             \$140 (\$290)         0.687
  Outpatient prescription costs, mean (SD)            \$3749 (\$3312)           \$3681 (\$3596)       0.555
  Total costs, mean (SD)                              \$16,600 (\$14,450)       \$15,090 (\$13,399)   0.001
  **Quarterly healthcare costs (PPPM)**                                                               
  0--90 days postindex, *n*                           1381                      2583                  
   Total costs, mean (SD)                             \$22,777 (\$19,074)       \$19,460 (\$16,064)   \<0.001
  91--180 days postindex, *n*                         1299                      2286                  
   Total costs, mean (SD)                             \$24,402 (\$24,760)       \$19,235 (\$19,769)   \<0.001
  181--270 days postindex, *n*                        1168                      1986                  
   Total costs, mean (SD)                             \$15,766 (\$21,032)       \$14,052 (\$18,286)   0.008
  271--360 days postindex, *n*                        1026                      1682                  
   Total costs, mean (SD)                             \$11,955 (\$15,774)       \$11,518 (\$15,756)   0.404

ER, emergency department (room); PN, peripheral neuropathy; PPPM, per patient per month; SD, standard deviation.

[Table 4](#table4-2040620719839025){ref-type="table"} contrasts the PPPM costs for patients who had a PN diagnosis during a particular line of therapy with patients who did not have a PN diagnosis during that same line. The PN patients' total costs were significantly higher during the first line of therapy (\$23,183 (SD \$22,243) *versus* \$20,790 (SD \$27,748); *p* = 0.007) and second line (\$37,880 (SD \$58,007) *versus* \$29,694 (SD \$103,457); *p* = 0.198) compared with patients without a PN diagnosis during those lines. This difference was primarily driven by outpatient medical costs, and particularly by outpatient hospital-based visits.

###### 

Per-patient-per-month all-cause healthcare costs by line of therapy stratified by patients with and without PN.

![](10.1177_2040620719839025-table4)

                                                 Line of therapy                                                
  ---------------------------------------------- --------------------------------------- ---------------------- -----------
  Inpatient-admission costs, mean (SD)           \$6158 (\$18,095)                       \$5000 (\$24,001)      0.127
  Outpatient medical costs, mean (SD)            \$12,598 (\$11,306)                     \$10,949 (\$11,319)    \<0.001
   ER costs, mean (SD)                           \$180 (\$798)                           \$129 (\$766)          0.055
   Outpatient office-visit costs, mean (SD)      \$318 (\$659)                           \$281 (\$522)          0.062
   Outpatient hospital-based visits, mean (SD)   \$7687 (\$10,244)                       \$6049 (\$9927)        \<0.001
   Laboratory-testing costs, mean (SD)           \$212 (\$552)                           \$197 (\$454)          0.376
  Outpatient prescription costs, mean (SD)       \$4427 (\$4103)                         \$4841 (\$6715)        0.043
  Total costs, mean (SD)                         \$23,183 (\$22,243)                     \$20,790 (\$27,748)    0.007
                                                 Second-line therapy                                            
                                                 PN second line                          No PN second line      *p* value
                                                 *n* = 280                               *n* = 1532             
  Inpatient-admission costs, mean (SD)           \$15,726 (\$51,561)                     \$11,468 (\$99,972)    0.487
  Outpatient medical costs, mean (SD)            \$15,807 (\$22,951)                     \$11,277 (\$18,854)    \<0.001
   ER costs, mean (SD)                           \$271 (\$2811)                          \$133 (\$879)          0.119
   Outpatient office-visit costs, mean (SD)      \$244 (\$325)                           \$240 (\$483)          0.889
   Outpatient hospital-based visits, mean (SD)   \$11,250 (\$21,747)                     \$7176 (\$17,414)      0.001
   Laboratory-testing costs, mean (SD)           \$173 (\$546)                           \$149 (\$441)          0.428
  Outpatient prescription costs, mean (SD)       \$6348 (\$6,192)                        \$6950 (\$9282)        0.297
  Total costs, mean (SD)                         \$37,880 (\$58,007)                     \$29,694 (\$103,457)   0.198
                                                 Third and subsequent lines of therapy                          
                                                 PN third+ line                          No PN third+ line      *p* value
                                                 *n* = 75                                *n* = 1028             
  Inpatient-admission costs, mean (SD)           \$7228 (\$19,480)                       \$6488 (\$27,591)      0.820
  Outpatient medical costs, mean (SD)            \$9803 (\$12,438)                       \$10,563 (\$15,657)    0.681
   ER costs, mean (SD)                           \$148 (\$347)                           \$126 (\$784)          0.812
   Outpatient office-visit costs, mean (SD)      \$235 (\$256)                           \$224 (\$351)          0.787
   Outpatient hospital-based visits, mean (SD)   \$7414 (\$11,805)                       \$6240 (\$13,760)      0.472
   Laboratory-testing costs, mean (SD)           \$70 (\$174)                            \$147 (\$440)          0.132
  Outpatient prescription costs, mean (SD)       \$8563 (\$7307)                         \$7777 (\$11,021)      0.543
  Total costs, mean (SD)                         \$25,594 (\$26,656)                     \$24,827 (\$34,532)    0.851

ER, emergency department (room); PN, peripheral neuropathy; PPPM, per patient per month; SD, standard deviation.

Discussion {#section16-2040620719839025}
==========

This study found significantly higher healthcare resource utilization and costs in patients with a post-treatment diagnosis for PN during their follow up compared with a matched group of patients without PN. Patients with PN were significantly more likely to be hospitalized, had an ER visit, had an outpatient hospital-based visit, and filled more outpatient prescriptions than matched patients without a PN diagnosis. This increased use of healthcare resource was associated with \$1509 higher PPPM total costs, amounting to \$36,216 over PN patients' mean 2-year follow-up time. Pike and colleagues, in a similar study using administrative US claims data (1999--2006), estimated the costs for chemotherapy-induced PN in a matched cohort comparison of cancer patients (not MM) with and without post-treatment PN, finding that PN patients had higher mean total healthcare costs by \$17,344 during the 12-month study period than comparable patients without PN. They further found that more PN cases were hospitalized, had an ER visit, and had other outpatient visits.^[@bibr24-2040620719839025]^ In a 2001 pilot study of chemotherapy-induced toxicity in ovarian cancer patients, Calhoun and colleagues found indirect costs, such as the cost of caregiver time and lost wages, to be a substantial contributor to the total burden of chemotherapy-induced toxicity.^[@bibr25-2040620719839025]^ The estimated marginal healthcare expenditure of \$1509 PPPM attributable to PN in our study using direct medical and prescription expenditures derived from paid healthcare claims represents only a portion of the overall societal cost. Due to the lack of information, costs associated with caregiver burden, indirect costs, or the quality of life impact were not examined.

In our study, the rate of PN in MM patients was 15.5%, which appears low compared with other studies where PN rates ranged from over 20% to as high as 70%^[@bibr15-2040620719839025],[@bibr16-2040620719839025],[@bibr26-2040620719839025],[@bibr27-2040620719839025]^ This may be attributable to several contributing factors. The diagnosis of PN may be under-reported in claims, as healthcare providers may only include the diagnosis when the presentation of PN is severe or substantially affecting disease management. Patients expecting drug side effects may not seek treatment for mild PN. This was confirmed by the finding of Yong et al. using chart review data. Yong and colleagues found that although more than 45% of MM patients had PN, less than 4% had grade 3 or 4 PN during the first four lines of therapy.^[@bibr27-2040620719839025]^ Clinical trials have also reported a much lower PN rate of grade 3--4 than PN rate of grade 1--2.^[@bibr16-2040620719839025]^ Some patients indexing in the latter years of the study may have experienced PN after the end of their available data. The incidence rate reported in our study of 9.1 PN cases per 100 person-years may likewise reflect a similar underestimate. In addition, it was estimated that 3.2% of MM patients have baseline PN.^[@bibr21-2040620719839025]^ In the current study, patients with baseline PN who later had another PN diagnosis post-treatment were excluded from the PN rate calculation, which may further lower the estimated PN rate. This exclusion was applied so as not to overestimate PN.

Our cohorts were demographically similar to the US MM population in terms of age and sex based on the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program's reporting most patients diagnosed between 65 and 74 years of age, median age 69 at initial diagnosis, and the SEER and American Cancer Society's estimate of 59% male--41% female incidence. The population in this study is slightly younger overall due to larger representation from commercial carriers than from Medicare data providers.^[@bibr1-2040620719839025],[@bibr2-2040620719839025]^

Obtaining optimal clinical efficacy requires carefully balancing treatment effectiveness with the potential for negative consequences on the patient's quality of life. The dosage reductions, treatment switches, or discontinuation of MM therapies to manage PN may ultimately affect response to therapy.^[@bibr28-2040620719839025]^ Thalidomide and bortezomib are associated with higher rates of PN.^[@bibr12-2040620719839025],[@bibr13-2040620719839025],[@bibr15-2040620719839025],[@bibr16-2040620719839025]^ Recent approval of novel therapies^[@bibr29-2040620719839025][@bibr30-2040620719839025][@bibr31-2040620719839025]--[@bibr32-2040620719839025]^ hold promise for antimyeloma efficacy with reduced incidence of PN.

Limitations {#section17-2040620719839025}
===========

There are several limitations associated with this study. Use of diagnosis coding from administrative claims data may be subject to misclassification errors, where the extent of undercoding for the selected conditions or comorbidities is unknown, and without the availability of patient charts or physician attestations. PN diagnoses may not be included on administrative claims unless the impairment significantly affects patient management, thereby under-reported or biased toward more severe cases. PN could not be identified directly in claims data because of the lack of diagnosis codes specific to disease-related and treatment-induced PN. Consequently, PN identification used an algorithm from a previously published study that has not been validated, and the PN could be due to other causes. This study used propensity-score matching to ensure cohorts had similar baseline demographic and clinical characteristics, increasing the likelihood that differences between cohorts were associated with PN. However, there is always the potential of unmeasured confounders outside of this study's data sources. In addition, the incremental healthcare utilization and costs in the PN cohort may not be directly linked to PN; it could also be due to PN treatment, PN complications, and other conditions that could not be controlled or adjusted for in the claims data. Pharmacological treatments that were based on pharmacy prescription claims only indicated that prescriptions were received, not necessarily how the patients took the medications. This is not an issue for medications administered in the physician's office and billed through a medical claim. Several drugs (carfilzomib, pomalidomide, panobinostat) entered the US market more recently (since 2012), resulting in limited sample sizes for these agents, so PN rates specific to individual medications were not examined. MarketScan® Commercial and Medicare databases are convenience samples of employees, retirees, and dependents with US Commercial and Medicare health-insurance coverage, therefore results from these databases may not be generalizable to populations with other healthcare coverage (e.g. Medicaid), or those lacking coverage.

Conclusion {#section18-2040620719839025}
==========

PN was observed in 15.5% of MM patients, and was associated with a significant economic burden, adding an average of \$1509 monthly per patient to the cost of MM treatment, as well as adding to the complexity of treatment with detrimental impact to patients. These results suggest that utilization of newer, more effective novel treatments might ease the economic and disease burden for MM associated with PN.
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###### 

ICD-9 and ICD-10 diagnosis codes of peripheral neuropathy.
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  ICD-9-CM diagnosis code        Description
  ------------------------------ ------------------------------------------------------------------------------------------------------------------
  337.20                         Reflex sympathetic dystrophy, unspecified
  337.21                         Reflex sympathetic dystrophy of the upper limb
  337.22                         Reflex sympathetic dystrophy of the lower limb
  337.29                         Reflex sympathetic dystrophy of other specified site
  353.0                          Brachial plexus lesions
  353.2                          Cervical root lesions, not elsewhere classified
  353.4                          Lumbosacral root lesions, not elsewhere classified
  355.71                         Causalgia of lower limb
  355.79                         Other mononeuritis of lower limb
  355.9                          Mononeuritis of unspecified site
  357.0                          Acute infective polyneuritis
  357.1                          Polyneuropathy in collagen vascular disease
  357.2                          Polyneuropathy in diabetes
  357.3                          Polyneuropathy in malignant disease
  357.4                          Polyneuropathy in other diseases classified elsewhere
  357.5                          Alcoholic polyneuropathy
  357.6                          Polyneuropathy due to drugs
  357.7                          Polyneuropathy due to other toxic agents
  357.81                         Chronic inflammatory demyelinating polyneuritis
  357.82                         Critical illness polyneuropathy
  357.89                         Other inflammatory and toxic neuropathy
  357.9                          Unspecified inflammatory and toxic neuropathies
  377.34                         Toxic optic neuropathy
  729.2                          Neuralgia, neuritis, and radiculitis, unspecified
  782.0                          Disturbance of skin sensation
  **ICD-10-CM diagnosis code**   **Code description**
  G9050                          Complex regional pain syndrome I, unspecified
  G90513                         Complex regional pain syndrome I of upper limb, bilateral
  G90511                         Complex regional pain syndrome I of right upper limb
  G90512                         Complex regional pain syndrome I of left upper limb
  G90519                         Complex regional pain syndrome I of unspecified upper limb
  G90521                         Complex regional pain syndrome I of right lower limb
  G90529                         Complex regional pain syndrome I of unspecified lower limb
  G90522                         Complex regional pain syndrome I of left lower limb
  G90523                         Complex regional pain syndrome I of lower limb, bilateral
  G9059                          Complex regional pain syndrome I of other specified site
  G540                           Brachial plexus disorders
  G55                            Nerve root and plexus compressions in diseases classified elsewhere
  G542                           Cervical root disorders, not elsewhere classified
  G544                           Lumbosacral root disorders, not elsewhere classified
  E0841                          Diabetes mellitus due to underlying condition with diabetic mononeuropathy
  E0941                          Drug or chemical-induced diabetes mellitus with neurological complications with diabetic mononeuropathy
  E1041                          Type 1 diabetes mellitus with diabetic mononeuropathy
  E1141                          Type 2 diabetes mellitus with diabetic mononeuropathy
  E1341                          Other specified diabetes mellitus with diabetic mononeuropathy
  G5770                          Causalgia of unspecified lower limb
  G5771                          Causalgia of right lower limb
  G5772                          Causalgia of left lower limb
  G5773                          Causalgia of bilateral lower limbs
  G59                            Mononeuropathy in diseases classified elsewhere
  G5780                          Other specified mononeuropathies of unspecified lower limb
  G5781                          Other specified mononeuropathies of right lower limb
  G5782                          Other specified mononeuropathies of left lower limb
  G5783                          Other specified mononeuropathies of bilateral lower limbs
  G588                           Other specified mononeuropathies
  G589                           Mononeuropathy, unspecified
  G64                            Other disorders of peripheral nervous system
  G610                           Guillain--Barré syndrome
  M0550                          Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site
  M05511                         Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder
  M05512                         Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
  M05519                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder
  M05521                         Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow
  M05522                         Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow
  M05529                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow
  M05531                         Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist
  M05532                         Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist
  M05539                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist
  M05541                         Rheumatoid polyneuropathy with rheumatoid arthritis of right hand
  M05542                         Rheumatoid polyneuropathy with rheumatoid arthritis of left hand
  M05549                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand
  M05551                         Rheumatoid polyneuropathy with rheumatoid arthritis of right hip
  M05552                         Rheumatoid polyneuropathy with rheumatoid arthritis of left hip
  M05559                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip
  M05561                         Rheumatoid polyneuropathy with rheumatoid arthritis of right knee
  M05562                         Rheumatoid polyneuropathy with rheumatoid arthritis of left knee
  M05569                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee
  M05571                         Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot
  M05572                         Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot
  M05579                         Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot
  M0559                          Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites
  E0840                          Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified
  E0842                          Diabetes mellitus due to underlying condition with diabetic polyneuropathy
  E0940                          Drug or chemical-induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified
  E0942                          Drug or chemical-induced diabetes mellitus with neurological complications with diabetic polyneuropathy
  E1040                          Type 1 diabetes mellitus with diabetic neuropathy, unspecified
  E1042                          Type 1 diabetes mellitus with diabetic polyneuropathy
  E1140                          Type 2 diabetes mellitus with diabetic neuropathy, unspecified
  E1142                          Type 2 diabetes mellitus with diabetic polyneuropathy
  E1340                          Other specified diabetes mellitus with diabetic neuropathy, unspecified
  E1342                          Other specified diabetes mellitus with diabetic polyneuropathy
  G130                           Paraneoplastic neuromyopathy and neuropathy
  G131                           Other systemic atrophy primarily affecting central nervous system in neoplastic disease
  A3683                          Diphtheritic polyneuritis
  A5215                          Late syphilitic neuropathy
  G63                            Polyneuropathy in diseases classified elsewhere
  M3483                          Systemic sclerosis with polyneuropathy
  G621                           Alcoholic polyneuropathy
  G611                           Serum neuropathy
  G620                           Drug-induced polyneuropathy
  G622                           Polyneuropathy due to other toxic agents
  G6282                          Radiation-induced polyneuropathy
  G6181                          Chronic inflammatory demyelinating polyneuritis
  G6281                          Critical illness polyneuropathy
  G6189                          Other inflammatory polyneuropathies
  G6289                          Other specified polyneuropathies
  G619                           Inflammatory polyneuropathy, unspecified
  G629                           Polyneuropathy, unspecified
  H463                           Toxic optic neuropathy
  M5410                          Radiculopathy, site unspecified
  M5418                          Radiculopathy, sacral and sacrococcygeal region
  M792                           Neuralgia and neuritis, unspecified
  R200                           Anesthesia of skin
  R201                           Hypoesthesia of skin
  R202                           Paresthesia of skin
  R203                           Hyperesthesia
  R208                           Other disturbances of skin sensation
  R209                           Unspecified disturbances of skin sensation

ICD-9-CM, International Classification of Diseases, ninth revision, Clinical Modification; ICD-10, tenth revision.

###### 

Demographic and baseline clinical characteristics of first-line therapy.
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  Demographic characteristics                        First-line therapy                           
  -------------------------------------------------- -------------------- ------- ------- ------- -------
  **Age (mean, SD)**                                 64.0                 10.81   64.2    11.61   0.661
  **Age group (*n*, %)**                                                                          
   18--34                                            4                    0.3%    9       0.3%    1.000
   35--44                                            36                   2.8%    95      3.5%    0.255
   45--54                                            204                  16.1%   429     16.0%   0.914
   55--64                                            459                  36.2%   1021    38.0%   0.283
   65--74                                            333                  26.3%   555     20.7%   0.000
   75+                                               231                  18.2%   578     21.5%   0.017
  **Sex (*n*, %)**                                                                                
   Male                                              761                  60.1%   1621    60.3%   0.874
   Female                                            506                  39.9%   1066    39.7%   0.874
  **Payer (*n*, %)**                                                                              
   Commercial                                        690                  54.5%   1536    57.2%   0.110
   Medicare                                          577                  45.5%   1151    42.8%   0.110
  **Insurance plan type (*n*, %)**                                                                
   Comprehensive                                     259                  20.4%   503     18.7%   0.200
   Exclusive-provider organization                   4                    0.3%    19      0.7%    0.131
   Health-maintenance organization                   141                  11.1%   321     11.9%   0.455
   Point of service (POS)                            66                   5.2%    147     5.5%    0.734
   Preferred-provider organization                   704                  55.6%   1508    56.1%   0.742
   POS with capitation                               8                    0.6%    14      0.5%    0.663
   Consumer-driven healthplan                        60                   4.7%    116     4.3%    0.552
   High-deductible healthplan                        25                   2.0%    59      2.2%    0.651
   Unknown                                           0                    0.0%    0       0.0%    
  **Geographic region (*n*, %)**                                                                  
   Northeast                                         217                  17.1%   488     18.2%   0.428
   North central                                     372                  29.4%   744     27.7%   0.276
   South                                             448                  35.4%   1011    37.6%   0.168
   West                                              221                  17.4%   410     15.3%   0.080
   Unknown                                           9                    0.7%    34      1.3%    0.116
  **Population density (*n*, %**)                                                                 
   Urban                                             1086                 85.7%   2276    84.7%   0.406
   Rural                                             172                  13.6%   379     14.1%   0.654
   Unknown                                           9                    0.7%    32      1.2%    0.164
  **Duration of line of therapy (mean, SD)**         234.9                219.9   244.6   241.2   0.222
  **DCI (mean, SD)**                                 4.5                  2.84    4.5     2.86    0.581
  **DCI (*n*, %)**                                                                                
   0                                                 11                   0.9%    21      0.8%    0.777
   1                                                 12                   0.9%    13      0.5%    0.086
   2                                                 402                  31.7%   900     33.5%   0.270
   3+                                                842                  66.5%   1753    65.2%   0.452
  **DCI components (*n*, %)**                                                                     
   Myocardial infarction                             46                   3.6%    87      3.2%    0.523
   Congestive heart failure                          100                  7.9%    217     8.1%    0.843
   Peripheral vascular disease                       53                   4.2%    112     4.2%    0.983
   Cerebrovascular disease                           87                   6.9%    179     6.7%    0.810
   Dementia                                          2                    0.2%    7       0.3%    0.727
   Chronic pulmonary disease                         206                  16.3%   417     15.5%   0.551
   Rheumatologic disease                             30                   2.4%    60      2.2%    0.791
   Peptic ulcer disease                              19                   1.5%    50      1.9%    0.418
   Mild liver disease                                10                   0.8%    15      0.6%    0.392
   Diabetes (mild to moderate)                       286                  22.6%   561     20.9%   0.225
   Diabetes with chronic complications               93                   7.3%    144     5.4%    0.014
   Hemiplegia or paraplegia                          5                    0.4%    11      0.4%    0.946
   Renal disease                                     285                  22.5%   573     21.3%   0.405
   Moderate or severe liver disease                  2                    0.2%    5       0.2%    1.000
   Human immunodeficiency virus                      3                    0.2%    6       0.2%    1.000
   Any malignancy, including lymphoma and leukemia   1094                 86.3%   2339    87.0%   0.542
   Metastatic solid tumor                            190                  15.0%   417     15.5%   0.670
  **Prior primary cancer (*n*, %)**                                                               
   Solid tumor                                       309                  24.4%   647     24.1%   0.832
   Hematologic cancer                                157                  12.4%   363     13.5%   0.332
  **Preperiod events of interest (*n*, %)**                                                       
   Chronic kidney disease                            243                  19.2%   503     18.7%   0.730
   End-stage renal disease/renal failure             84                   6.6%    170     6.3%    0.717
   Skeletal-related events                           610                  48.1%   1303    48.5%   0.838
   Hypercalcemia                                     172                  13.6%   361     13.4%   0.904
   Venous thromboembolism                            52                   4.1%    120     4.5%    0.603
   Neutropenia                                       42                   3.3%    93      3.5%    0.813
   Pneumonia                                         123                  9.7%    251     9.3%    0.713
   Major bleeding                                    26                   2.1%    52      1.9%    0.805
   GI bleeding                                       63                   5.0%    141     5.2%    0.715
   Anemia                                            718                  56.7%   1504    56.0%   0.681
   Anemia or anemia treatment                        720                  56.8%   1514    56.3%   0.776
   Thrombocytopenia                                  95                   7.5%    188     7.0%    0.568
   Amyloidosis                                       49                   3.9%    88      3.3%    0.342

DCI, Deyo--Charlson Comorbidity Index; GI, gastrointestinal; PN, peripheral neuropathy; SD, standard deviation.

###### 

Demographic and baseline clinical characteristics of second-line therapy.
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  Demographic characteristics                        Second-line therapy                           
  -------------------------------------------------- --------------------- ------- ------- ------- -------
  **Age (mean, SD)**                                 62.8                  10.35   62.3    11.09   0.418
  **Age group (*n*, %)**                                                                           
   18--34                                            4                     1.4%    6       0.4%    0.054
   35--44                                            5                     1.8%    60      3.9%    0.078
   45--54                                            47                    16.8%   309     20.2%   0.190
   55--64                                            110                   39.3%   617     40.3%   0.756
   65--74                                            74                    26.4%   281     18.3%   0.002
   75+                                               40                    14.3%   259     16.9%   0.277
  **Sex (*n*, %**)                                                                                 
   Male                                              178                   63.6%   926     60.4%   0.324
   Female                                            102                   36.4%   606     39.6%   0.324
  **Payer (*n*, %)**                                                                               
   Commercial                                        164                   58.6%   981     64.0%   0.081
   Medicare                                          116                   41.4%   551     36.0%   0.081
  **Insurance plan type (*n*, %)**                                                                 
   Comprehensive                                     46                    16.4%   260     17.0%   0.824
   Exclusive-provider organization                   2                     0.7%    16      1.0%    1.000
   Health-maintenance organization                   43                    15.4%   188     12.3%   0.155
   Point of service (POS)                            17                    6.1%    96      6.3%    0.901
   Preferred-provider organization                   150                   53.6%   854     55.7%   0.501
   POS with capitation                               2                     0.7%    9       0.6%    0.682
   Consumer-driven health plan                       12                    4.3%    76      5.0%    0.629
   High-deductible health plan                       8                     2.9%    33      2.2%    0.467
   Unknown                                           0                     0.0%    0       0.0%    
  **Geographic region (*n*, %)**                                                                   
   Northeast                                         51                    18.2%   256     16.7%   0.537
   North central                                     70                    25.0%   431     28.1%   0.281
   South                                             107                   38.2%   582     38.0%   0.943
   West                                              50                    17.9%   249     16.3%   0.506
   Unknown                                           2                     0.7%    14      0.9%    1.000
  **Population density (*n*, %)**                                                                  
   Urban                                             242                   86.4%   1,294   84.5%   0.400
   Rural                                             36                    12.9%   224     14.6%   0.439
   Unknown                                           2                     0.7%    14      0.9%    1.000
  **Duration of line of therapy (mean, SD)**         171.2                 199.7   201.0   249.9   0.059
  **DCI (mean, SD)**                                 4.7                   2.95    4.3     2.78    0.03
  **DCI (*n*, %**)                                                                                 
   0                                                 1                     0.4%    18      1.2%    0.340
   1                                                 1                     0.4%    8       0.5%    1.000
   2                                                 96                    34.3%   547     35.7%   0.648
   3+                                                182                   65.0%   959     62.6%   0.444
  **DCI components (*n*, %**)                                                                      
   Myocardial infarction                             11                    3.9%    43      2.8%    0.310
   Congestive heart failure                          16                    5.7%    92      6.0%    0.850
   Peripheral vascular disease                       7                     2.5%    53      3.5%    0.409
   Cerebrovascular disease                           19                    6.8%    92      6.0%    0.617
   Dementia                                          0                     0.0%    4       0.3%    
   Chronic pulmonary disease                         44                    15.7%   225     14.7%   0.657
   Rheumatologic disease                             3                     1.1%    32      2.1%    0.255
   Peptic ulcer disease                              7                     2.5%    28      1.8%    0.452
   Mild liver disease                                1                     0.4%    6       0.4%    1.000
   Diabetes (mild to moderate)                       66                    23.6%   311     20.3%   0.215
   Diabetes with chronic complications               20                    7.1%    70      4.6%    0.068
   Hemiplegia or paraplegia                          0                     0.0%    9       0.6%    
   Renal disease                                     73                    26.1%   334     21.8%   0.115
   Moderate or severe liver disease                  0                     0.0%    2       0.1%    
   Human immunodeficiency virus                      0                     0.0%    6       0.4%    
   Any malignancy, including lymphoma and leukemia   247                   88.2%   1,434   93.6%   0.001
   Metastatic solid tumor                            50                    17.9%   244     15.9%   0.421
  **Prior primary cancer (*n*, %**)                                                                
   Solid tumor                                       59                    21.1%   325     21.2%   0.957
   Hematologic cancer                                40                    14.3%   189     12.3%   0.367
  **Preperiod events of interest (*n*, %)**                                                        
   Chronic kidney disease                            59                    21.1%   250     16.3%   0.052
   End-stage renal disease/renal failure             14                    5.0%    76      5.0%    0.978
   Skeletal-related events                           138                   49.3%   738     48.2%   0.732
   Hypercalcemia                                     41                    14.6%   222     14.5%   0.947
   Venous thromboembolism                            13                    4.6%    64      4.2%    0.723
   Neutropenia                                       7                     2.5%    50      3.3%    0.501
   Pneumonia                                         22                    7.9%    129     8.4%    0.754
   Major bleeding                                    5                     1.8%    22      1.4%    0.595
   GI bleeding                                       15                    5.4%    77      5.0%    0.817
   Anemia                                            163                   58.2%   825     53.9%   0.178
   Anemia or anemia treatment                        163                   58.2%   829     54.1%   0.205
   Thrombocytopenia                                  29                    10.4%   100     6.5%    0.022
   Amyloidosis                                       10                    3.6%    34      2.2%    0.177

DCI, Deyo--Charlson Comorbidity Index; GI, gastrointestinal; PN, peripheral neuropathy; SD, standard deviation.
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  Demographic characteristics                        Third and subsequent line of therapy                           
  -------------------------------------------------- -------------------------------------- ------- ------- ------- -------
  **Age (mean, SD)**                                 62.0                                   9.57    61.2    10.72   0.517
  **Age group (*n*, %)**                                                                                            
   18--34                                            0                                      0.0%    7       0.7%    
   35--44                                            2                                      2.7%    44      4.3%    0.764
   45--54                                            14                                     18.7%   227     22.1%   0.490
   55--64                                            31                                     41.3%   408     39.7%   0.779
   65--74                                            19                                     25.3%   210     20.4%   0.312
   75+                                               9                                      12.0%   132     12.8%   0.833
  **Sex (*n*, %)**                                                                                                  
   Male                                              50                                     66.7%   617     60.0%   0.256
   Female                                            25                                     33.3%   411     40.0%   0.256
  **Payer (*n*, %)**                                                                                                
   Commercial                                        45                                     60.0%   671     65.3%   0.356
   Medicare                                          30                                     40.0%   357     34.7%   0.356
  **Insurance plan type (*n*, %)**                                                                                  
   Comprehensive                                     11                                     14.7%   176     17.1%   0.585
   Exclusive-provider organization                   0                                      0.0%    7       0.7%    
   Health-maintenance organization                   9                                      12.0%   130     12.6%   0.871
   Point of service (POS)                            7                                      9.3%    74      7.2%    0.494
   Preferred-provider organization                   42                                     56.0%   547     53.2%   0.640
   POS with capitation                               0                                      0.0%    5       0.5%    
   Consumer-driven health plan                       4                                      5.3%    66      6.4%    1.000
   High-deductible health plan                       2                                      2.7%    23      2.2%    0.685
   Unknown                                           0                                      0.0%    0       0.0%    
  **Geographic region (*n*, %)**                                                                                    
   Northeast                                         11                                     14.7%   188     18.3%   0.431
   North central                                     13                                     17.3%   283     27.5%   0.054
   South                                             30                                     40.0%   356     34.6%   0.347
   West                                              21                                     28.0%   195     19.0%   0.057
   Unknown                                           0                                      0.0%    6       0.6%    
  **Population density (*n*, %)**                                                                                   
   Urban                                             64                                     85.3%   900     87.5%   0.577
   Rural                                             11                                     14.7%   122     11.9%   0.472
   Unknown                                           0                                      0.0%    6       0.6%    0.507
  **Duration of line of therapy (mean, SD)**         244.0                                  275.6   196.2   239.1   0.099
  **DCI (mean, SD)**                                 4.3                                    2.84    4.0     2.55    0.274
  **DCI (*n*, %)**                                                                                                  
   0                                                 0                                      0.0%    15      1.5%    0.292
   1                                                 0                                      0.0%    0       0.0%    NA
   2                                                 29                                     38.7%   399     38.8%   0.98
   3+                                                46                                     61.3%   614     59.7%   0.784
  **DCI components (*n*, %)**                                                                                       
   Myocardial infarction                             0                                      0.0%    16      1.6%    
   Congestive heart failure                          2                                      2.7%    32      3.1%    1.000
   Peripheral vascular disease                       3                                      4.0%    27      2.6%    0.452
   Cerebrovascular disease                           6                                      8.0%    66      6.4%    0.625
   Dementia                                          0                                      0.0%    2       0.2%    
   Chronic pulmonary disease                         12                                     16.0%   150     14.6%   0.739
   Rheumatologic disease                             2                                      2.7%    13      1.3%    0.272
   Peptic ulcer disease                              0                                      0.0%    16      1.6%    
   Mild liver disease                                3                                      4.0%    4       0.4%    0.009
   Diabetes (mild to moderate)                       13                                     17.3%   210     20.4%   0.519
   Diabetes with chronic complications               2                                      2.7%    54      5.3%    0.581
   Hemiplegia or paraplegia                          1                                      1.3%    1       0.1%    0.131
   Renal disease                                     14                                     18.7%   218     21.2%   0.602
   Moderate or severe liver disease                  0                                      0.0%    2       0.2%    
   Human immunodeficiency virus                      0                                      0.0%    1       0.1%    
   Any malignancy, including lymphoma and leukemia   74                                     98.7%   1000    97.3%   0.716
   Metastatic solid tumor                            13                                     17.3%   140     13.6%   0.369
  **Prior primary cancer (*n*, %)**                                                                                 
   Solid tumor                                       19                                     25.3%   215     20.9%   0.366
   Hematologic cancer                                11                                     14.7%   125     12.2%   0.524
  **Preperiod events of interest (*n*, %)**                                                                         
   Chronic kidney disease                            11                                     14.7%   168     16.3%   0.704
   End-stage renal disease/renal failure             2                                      2.7%    48      4.7%    0.573
   Skeletal-related events                           42                                     56.0%   486     47.3%   0.144
   Hypercalcemia                                     10                                     13.3%   115     11.2%   0.571
   Venous thromboembolism                            1                                      1.3%    38      3.7%    0.512
   Neutropenia                                       2                                      2.7%    28      2.7%    1.000
   Pneumonia                                         5                                      6.7%    84      8.2%    0.644
   Major bleeding                                    2                                      2.7%    13      1.3%    0.272
   GI bleeding                                       3                                      4.0%    46      4.5%    1.000
   Anemia                                            36                                     48.0%   550     53.5%   0.357
   Anemia or anemia treatment                        36                                     48.0%   554     53.9%   0.323
   Thrombocytopenia                                  7                                      9.3%    62      6.0%    0.224
   Amyloidosis                                       0                                      0.0%    18      1.8%    0.248

DCI, Deyo--Charlson Comorbidity Index; GI, gastrointestinal; NA, not applicaple; PN, peripheral neuropathy; SD, standard deviation.
